The US Food and Drug Administration has approved Roche Holding AG’s personalised cancer treatment, which targets tumours with specific genetic mutations, irrespective of where in the body the disease started, reports Reuters Health. The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling. It is approved to treat certain types of solid tumours, which show rare genetic anomalies called NTRK fusions.
Individually, the mutations are rare and it is difficult to run dedicated tests for each. They have been identified in a broad range of solid tumour types, including breast, colorectal, pancreatic and non-small cell lung cancers, the company said.
The report says the FDA also approved it to treat adult patients with non-small cell lung cancer, whose tumours show a genetic mutation called ROS1 fusion. Rival treatment Vitrakvi from German drugmaker Bayer has already won US backing for solid tumours that test positive for NTRK genes.
[link url="https://www.reuters.com/article/us-roche-hldg-fda/roches-personalized-cancer-treatment-wins-fda-approval-idUSKCN1V52AW"]Reuters Health report[/link]